172nd ENMC International workshop: Dysferlinopathies 29-31 january 2010, naarden, the netherlands

Neuromuscular Disorders

Volumn 21, Issue 7, 2011, Pages 503-512

  Krahn, Martin ^a   Illa, Isabel ^b   Lévy, Nicolas ^a   Bushby, Kate ^c  

^a TIMONE HOSPITAL   (France)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFLAZACORT; DYSFERLIN; INFLAMMASOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PARVOVIRUS VECTOR; PLACEBO;

ANO5 GENE; ARTICLE; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; DISEASE MODEL; DRUG EFFECT; DYSF GENE; DYSFERLINOPATHY; EXON SKIPPING; GENE; GENE DELETION; GENE EXPRESSION; GENETIC SCREENING; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERNATIONAL COOPERATION; LIMB GIRDLE MUSCULAR DYSTROPHY; MISSENSE MUTATION; MIYOSHI MYOPATHY; MOLECULAR DIAGNOSIS; MONOCYTE; MUSCLE BIOPSY; MUSCLE REGENERATION; MUTATIONAL ANALYSIS; MYOBLAST; NETHERLANDS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STANDARDIZATION; TMEM16 GENE; UPREGULATION; VIRAL GENE THERAPY;

HUMANS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; NETHERLANDS;

EID: 79960075211     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.04.006     Document Type: Article

References (45)

1. De Luna N., Freixas A., Gallano P., et al. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord 2007, 17:69-76.
2. Guglieri M., Magri F., D'Angelo M.G., et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat 2008, 29:258-266.
3. Krahn M., Beroud C., Labelle V., et al. Analysis of the DYSF mutational spectrum in a large cohort of patients. Hum Mutat 2009, 30:E345-75.
4. Fanin M., Nascimbeni A.C., Aurino S., et al. Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes. Neurology 2009, 72:1432-1435.
5. Klinge L., Aboumousa A., Eagle M., et al. New aspects on patients affected by dysferlin deficient muscular dystrophy. J Neurol Neurosurg Psychiatry 2010, 81:946-953.
6. Illa I., De Luna N., Dominguez-Perles R., et al. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology 2007, 68:1284-1289.
7. Krahn M., Labelle V., Borges A., Bartoli M., Levy N. Exclusion of mutations in the dysferlin alternative exons 1 of DYSF-v1, 5a, and 40a in a cohort of 26 patients. Genet Test Mol Biomarkers 2010, 14:153-154.
8. Krahn M., Borges A., Navarro C., et al. Identification of different genomic deletions and one duplication in the dysferlin gene using multiplex ligation-dependent probe amplification and genomic quantitative PCR. Genet Test Mol Biomarkers 2009, 13:439-442.
9. Liu J., Aoki M., Illa I., Wu C., et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998, 20:31-36.
10. Bashir R., Britton S., Strachan T., et al. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 1998, 20:37-42.
11. Ho M., Gallardo E., McKenna-Yasek D., De Luna N., Illa I., Brown R.H. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol 2002, 51:129-133.
12. Linssen W.H., de Visser M., Notermans N.C., et al. Genetic heterogeneity in Miyoshi-type distal muscular dystrophy. Neuromuscul Disord 1998, 8:317-320.
13. Jaiswal J.K., Marlow G., Summerill G., et al. Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect. Traffic 2007, 8:77-88.
14. Bolduc V., Marlow G., Boycott K.M., et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010, 86:213-221.
15. Tsutsumi S., Kamata N., Vokes T.J., et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). Am J Hum Genet 2004, 74:1255-1261.
16. Hicks D., Sarkozy A., Muelas N., et al. A founder mutation in Anoctamin 5 is a major cause of limb-girdle muscular dystrophy. Brain 2011, 134:171-182.
17. Gallardo E., Rojas-Garcia R., de Luna N., Pou A., Brown R.H., Illa I. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 2001, 57:2136-2138.
18. De Luna N., Gallardo E., Sonnet C., et al. Role of thrombospondin 1 in macrophage inflammation in dysferlin myopathy. J Neuropathol Exp Neurol 2010, 69:643-653.
19. Bittner R.E., Anderson L.V., Burkhardt E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet 1999, 23:141-142.
20. Ho M., Post C.M., Donahue L.R., et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 2004, 13:1999-2010.
21. Rayavarapu S., Van der Meulen J.H., Gordish-Dressman H., Hoffman E.P., Nagaraju K., Knoblach S.M. Characterization of dysferlin deficient SJL/J mice to assess preclinical drug efficacy: fasudil exacerbates muscle disease phenotype. PLoS One 2010, 5:e12981.
22. Bansal D., Miyake K., Vogel S.S., et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 2003, 423:168-172.
23. Han R., Bansal D., Miyake K., et al. Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest 2007, 117:1805-1813.
24. Han R., Frett E.M., Levy J.R., et al. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest 2010, 120:4366-4374.
25. Millay D.P., Maillet M., Roche J.A., et al. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol 2009, 175:1817-1823.
26. von der Hagen M., Laval S.H., Cree L.M., et al. The differential gene expression profiles of proximal and distal muscle groups are altered in pre-pathological dysferlin-deficient mice. Neuromuscul Disord. 2005, 15:863-877.
27. Lostal W., Bartoli M., Bourg N., et al. Efficient recovery of dysferlin deficiency by dual adeno-associated vector-mediated gene transfer. Hum Mol Genet 2010, 19:1897-1907.
28. Roche J.A., Lovering R.M., Bloch R.J. Impaired recovery of dysferlin-null skeletal muscle after contraction-induced injury in vivo. Neuroreport 2008, 19:1579-1584.
29. Huang Y., Verheesen P., Roussis A., et al. Protein studies in dysferlinopathy patients using llama-derived antibody fragments selected by phage display. Eur J Hum Genet 2005, 13:721-730.
30. Huang Y., de Morree A., van Remoortere A., et al. Calpain 3 is a modulator of the dysferlin protein complex in skeletal muscle. Hum Mol Genet 2008, 17:1855-1866.
31. Huang Y., Laval S.H., van Remoortere A., et al. AHNAK, a novel component of the dysferlin protein complex, redistributes to the cytoplasm with dysferlin during skeletal muscle regeneration. FASEB J 2007, 21:732-742.
32. de Morree A., Hensbergen P.J., van Haagen H.H., et al. Proteomic analysis of the dysferlin protein complex unveils its importance for sarcolemmal maintenance and integrity. PLoS One 2010, 5:e13854.
33. Therrien C., Di Fulvio S., Pickles S., Sinnreich M. Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 2009, 48:2377-2384.
34. Azakir B.A., Di Fulvio S., Therrien C., Sinnreich M. Dysferlin interacts with tubulin and microtubules in mouse skeletal muscle. PLoS One 2010, 5:e10122.
35. Han R., Kanagawa M., Yoshida-Moriguchi T., et al. Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc Natl Acad Sci USA 2009, 106:12573-12579.
36. Chiu Y.H., Hornsey M.A., Klinge L., et al. Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy. Hum Mol Genet 2009, 18:1976-1989.
37. Jethwaney D, Islam MR, Leidal KG, et al. Proteomic analysis of plasma membrane and secretory vesicles from human neutrophils. Proteome Sci. 2007;5:12.
38. Wenzel K., Zabojszcza J., Carl M., et al. Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 2005, 175:6219-6225.
39. Kesari A., Fukuda M., Knoblach S., et al. Dysferlin deficiency shows compensatory induction of Rab27A/Slp2a that may contribute to inflammatory onset. Am J Pathol 2008, 173:1476-1487.
40. Nagaraju K., Rawat R., Veszelovszky E., et al. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol 2008, 172:774-785.
41. Nagaraju K., Casciola-Rosen L., Rosen A., et al. The inhibition of apoptosis in myositis and in normal muscle cells. J Immunol 2000, 164:5459-5465.
42. Rawat R., Cohen T.V., Ampong B., et al. Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol 2010, 176:2891-2900.
43. Krahn M, Wein N, Bartoli M, et al. A naturally occurring human minidysferlin protein repairs sarcolemmal lesions in a mouse model of dysferlinopathy. Sci Transl Med. 2010;2:50ra69.
44. Sinnreich M., Therrien C., Karpati G. Lariat branch point mutation in the dysferlin gene with mild limb-girdle muscular dystrophy. Neurology 2006, 66:1114-1116.
45. Wein N., Avril A., Bartoli M., et al. Efficient bypass of mutations in dysferlin deficient patient cells by antisense-induced exon skipping. Hum Mutat 2010, 31:136-142.